Liquid Biopsy
Liquid biopsy has the potential to revolutionize the cancer diagnosis and treatment market. Beyond clinical applications, liquid biopsies are already providing important information as part of drug development efforts. We believe liquid biopsy will be one of the most important growth areas in diagnostic tools in the coming decade.
What we’re watching:
- Clinical data and validations
- Reimbursement process
- Biopharma partnership agreements
- Progress of recent/pending commercial launches in asymptomatic screening and recurrence monitoring
Related themes:
1.5 Million
new cancer diagnoses in the U.S. each year
<5%
estimated current penetration of patients eligible to use liquid biopsy tools as a cancer companion diagnostic
>300 Million
people in the U.S. that could benefit from early cancer screening tools